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Abstract
Background: Many rare diseases of childhood are life-threatening and chronically debilitating, so living with a rare
disease is an on-going challenge for patients and their families. MPS is one of a range of rare inherited metabolic
disorders (IMDs) that come under category 3 of life-limiting conditions, where there is no curative treatment
available at present. Although the study of rare diseases is increasingly novel, and of clinical importance to the
population, the lack of empirical data in the field to support policy and strategy development is a compelling
argument for further research to be sought.
Methods: This qualitative hermeneutic phenomenological study explored and interpreted Irish parents’ experiences
of living with and caring for children, adolescents and young adults with MPS and the impact of these diseases on
their day to day life. A purposively selected sample of parents’ attending the Irish National Centre for Inherited
Metabolic Disorders was invited to participate in serial in-depth interviews.
Results: A total of eight parents’ (n = 8) of children with a range of MPS disorders aged from 6 months to 22 years
(MPS I Hurler syndrome, Scheie syndrome), MPS II (Hunter syndrome), MPS III (Sanfilipo syndrome) and MPS VI
(Maroteaux-Lamy syndrome) were interviewed at three time points over a 17 month period. The main themes
identified during data analysis were described as living with MPS, living with a genetic rare disease, the stigma of a
rare condition, MPS as encompassing multiple diseases, Unknown future, hospital vs. home, experience of waiting, a
tough road ahead, and things in their day-to-day life with MPS. They spoke of their child’s Quality of Life (QoL),
their healthy children’s wellbeing, and for some, the impact on their own physical and psychological wellbeing.
They also reflected on issues of stigmatisation and isolation in their experience of living with a child with a rare
disorder.
Conclusion: This study’s findings reflect the wider literature on the impact of rare diseases, which have also
indicated how caring for someone with MPS, a condition that is chronic, progressive and degenerative can impact
on all dimensions of the family’s life. Analysis of the findings using a hemenutic pheomenology perspecitve suggest
that parents of children with MPS experience multiple cyclical movements across all five human lived existential
experience, and they gradually develop ways to incorporate MPS in their day to day life. It was also evident that all
the carers in this study experienced a range of uncertainties, with parents using terms such as ‘no man’s land’ and
‘future is unknown’ to describe their world.
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Background
Mucopolysaccharidoses (MPS) is one of the many rare
inherited metabolic disorders (IMDs) which fall under
category 3 of life-limiting conditions [1–4, 5]. It is
caused by the body’s inability to produce specific lyso-
somal enzymes. This defective or missing lysosomal en-
zyme causes large amounts of complex sugar molecules
or glycosaminoglycan’s (GAG’s) to accumulate in harm-
ful amounts in the body's cells and tissues [1–4]. This
result in progressive cellular damage, which in turn leads
to an array of manifestations that worsen with age, and
can affect multiple organ systems, leading to cognitive
impairment and eventually resulting in severe morbidity
and premature death [1–4]. It is important to under-
stand that in almost all cases of MPS, the clinical fea-
ture(s) may not be visible at birth, and these children
apparently have normal development in the first years of
life but deteriorate as storage of GAGS affects organs
and tissues [1–3, 6]. Except for MPS II, MPS are a gen-
etic disorder inherited in an autosomal recessive pattern
affecting both males and females [1–4]. Within MPS,
the wide-ranging clinical spectrum and varying degree of
severity mean that diagnosis can often be delayed [1, 3].
It has been reported that early diagnosis and treatment
can improve outcomes in MPS patients [7, 8]. Transplant-
ation of stem cells using bone marrow (Bone Marrow
Transplant)(BMT), haematopoietic stem cell transplant-
ation (HSCT) or umbilical cord blood (UCBT) has been
shown to be effective in slowing disease progression in
certain types of MPS [1–3, 9–11]. In other types of MPS
(I, II and VI), enzyme replacement therapy (ERT) in the
form of supportive treatments has shown benefits regard-
ing GAG’s reduction and increased distance walked as part
of the 6-minute walk test [1–3, 9–11]. Children with
Mucopolysaccharidoses (MPS) and their families antici-
pate an unknown lifespan since it is a progressive condi-
tion with a lack of curative treatment options available at
present, where treatment is exclusively palliative and may
commonly extend over many years [5].
A comprehensive review of the literature was under-
taken, focusing on the experience, impact, and conse-
quences of caring for a child with MPS. Currently, the
empirical body of knowledge on MPS is focused on the
pathophysiological and genetic aspect of the disease ra-
ther than parents’ rare disease journey and their experi-
ence of living with a child with this condition. A small
number of studies on the impact of parenting a child
with MPS III [12–17] and MPS I [18] were identified
and these studies report the experience as devastating,
with a heavy burden being placed on parents due to the
child’s severe behavioural and physical symptoms, as
well as the progressive nature of the condition itself.
However, no literature specifically examining the paren-
tal experience of caring for a child, adolescent and young
adult across the spectrum of MPS was found. One
Canadian study identified and explored the lived experi-
ence of parents with children diagnosed with MPS, who
had received Enzyme Replacement Treatment (ERT), but
were waiting for ongoing ERT funding to complete treat-
ment [19]. Developments in advanced supportive treat-
ment options such as ERT, BMT may have made dramatic
changes in the quality of life (QoL) for individuals with
certain forms of MPS. The WHO defines the quality of life
as a “broad ranging concept affected in a complex way by
the person's physical health, psychological state, the level of
independence, social relationships, personal beliefs and
their relationship to salient features of their environment”
[20] (p. 1). Despite these developments, in most cases
symptoms associated with the disease can affect multiple
areas of daily living and bring major impairment to the in-
dividual’s lifespan [2, 4].
Recent studies recommend further research into the
experience of caring for children with rare life-limiting
conditions, investigating the needs of families for the
long-term care of their child through adolescence to
adulthood, and the specific services required [13, 14, 21].
The UK Strategy for Rare Diseases [22] and the National
Rare Disease Plan for Ireland [23] and many more rare
diseases national strategies [24, 25] across European
member states highlight the importance of engaging and
involving patients and their families in research and
incorporating the patient and carers voices into the
policies and services that affect them. These strategy
documents have also highlighted the importance of estab-
lishing a variety of research approaches to rare diseases.
Qualitative healthcare research, which can be tailored to
explore the experience of living with a rare condition and
the challenges patients and their caregivers face in their
daily life, is becoming increasingly important. Given the
lack of current evidence, there is a need to make explicit
plan in developing and promoting best practice in care for
the families of children with MPS, and in doing so make
their lives more understandable to the wider healthcare
audience.
The aims of this study were:
(1)To understand and interpret parents’ experience of
living and caring for a child with MPS.
(2)To examine the knowledge and understanding of
MPS from the perspective of parents.
(3)To explore the impact of regular hospitalisation of
children living with Mucopolysaccharidoses (MPS)
on family life.
Methods
During this study, some qualitatively-orientated research
methodologies were examined in detail. Interpretive
qualitative research often reflects questions about social
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aspects of health and illness of “what,” “how” or “why”?
[26]. It is helpful where little is known about a topic or
evidence is sparse. Qualitative research also explores the
context of participants’ subjective experience. A hermen-
eutic phenomenological approach, informed by the
philosophical constructs of Heidegger [27] Gadamer [28,
29] and Van Manen [30–32] was undertaken to study
the complexities of a challenging life world [33]. Her-
meneutic phenomenology is concerned with the study of
lifeworld or human experience as we live it [30–33]. As
such, this specific methodology enables a deeper under-
standing situated within parents’ day-to-day lives, man-
aging and living with this condition in a family context,
and the factors that both enhance and inhibit that ex-
perience [34]. Van Manen, [29, 30] proposed that “her-
meneutic phenomenological research is a search for the
fullness of living” (pp.12). In this case, it is a search for
the way parents experiences the world as parents, and a
search for what it is to be parents of a child, adolescent
or young adult with MPS as a progressive life-limiting
condition. Through a hermeneutic phenomenological
approach, the uniqueness of this parent group was
respected and validated, and the opportunity was given
to share what may be concealed and unknown in their
experience. In this study, utilising hermeneutic phenom-
enology enabled access to parents’ reflection in a particu-
lar moment of time on their lived experience and
enabled a deeper understanding of the day-to-day chal-
lenges of living with a child, adolescent and young
adult with an MPS disease.
Recruitment
Given the rarity of the disease and relatively low numbers
of children diagnosed each year, families were recruited
from the outpatient clinic of the National Centre for
Inherited Metabolic Disorders (NCIMD), Ireland where
access to this specialist cohort group was more readily
available.
Inclusion Criteria
 A mother or father of a child, adolescent or young
adult (0–24 years old), with a diagnosed MPS
condition (I-IX)
 Parents of children who attend the NCIMD
 Parents currently residing in the Republic of Ireland
and receiving treatment for their child in Ireland
 Those able to communicate through English.
Exclusion Criteria
 Women who are pregnant at the time of data
collection were excluded from the study. The recall
of past experiences coupled with the fact that MPS
is inherited in an autosomal recessive pattern, could
potentially cause distress and exacerbate concern
that the expected baby might be diagnosed with the
same condition.
Data collection and analysis
A total of eight parents’ (n = 8) participated in this study
over a 17-month period. Data was collected through
three time point serial interviews, a total of 19 in-depth,
digitally-recorded interviews were completed, and each
interview lasted for 60–120 min. Among these, one of
the families only attended one set of interviews because
of their children were subsequently admitted to hospital
for treatment outside Ireland. All interviews were con-
ducted in the hospital setting as a requirement of ethical
approval for the study. At the time of interview, these
parents had children aged between 6 months to 22 years,
diagnosed with the following range of MPS disorders:
MPS I syndromes (Hurler syndrome, Scheie syndrome),
MPS II (Hunter syndrome), MPS III (Sanfilipo syn-
drome) and MPS VI (Maroteaux-Lamy syndrome). MPS
IV (Morquio syndrome) was not included in the final
sample. The small number of adults living with MPS IV
was excluded from the study due to the age of this pa-
tient cohort (over 24 years). The parent of an adolescent
with MPS IV initially agreed to participate in this study
but withdrew at a later stage because of the long journey
involved in attending for interview. All interviews were
conducted in the hospital setting in order to meet the
requirement of the research and ethics committee rec-
ommendation may have mitigated in accessing a complete
sample, given that some families lived a considerable
distance from the hospital. The serial interview ap-
proach provided an opportunity for the researcher and
the parents to return to and reflect on the themes raised
at the previous interview, thus enabling a process of inter-
pretive insight [30–32]. The thematic analysis involved the
use of Van Manen’s [31] three approaches: (1) the holistic
or sententious approach, (2) the selective or highlighting
approach, and (3) the detailed or line- by-line approach,
were used. This process helped to identify and isolate key
thematic aspects of the study phenomenon to prompt
subsequent interviews.
MPS being a rare “orphan” disease, which affects a very
small percentage of the population, the topic of anonymity
and confidentiality has been a major concern among rare
disease population-based research groups [35] Confidenti-
ality was, therefore, a priority for these family units, and
their identities were protected at all times, to prevent any
breach of confidentiality. A code was therefore assigned to
each family, and these codes were used throughout the
data analysis. These codes are found at the end of each
interview quote cited in the result section. For example,
“F1” stands for “Family 1”, and the letters “A, B and C”
stands for the “1st, 2nd, and 3rd interviews”, respectively.
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Van Manen’s [31, 32] five existential themes emerged
as a reflective data analysis framework following thematic
analysis of interview transcripts. These five fundamental
life world themes described the way humans experience
the world, and these are “Lived relation, Lived body, Lived
space, Lived time, and Lived things” [31, 32] underpinned
the data analysis and meaningful expression of the parents
day to day experience of living with MPS. Table 1 below
demonstrates Van Manen’s [31, 32] five Fundamental Ex-
istential of Human Experience.
Results
Nine themes and 22 corresponding subthemes (parents’
expressions) were identified during data analysis. The main
themes identified during data analysis were described as liv-
ing with MPS, living with a genetic rare disease, the stigma
of a rare condition, MPS as encompassing multiple dis-
eases, Unknown future, hospital vs. home, experience of
waiting, a tough road ahead, and things in their day-to-day
life with MPS. The following sections will discuss these
themes in the context of Van Manen’s five lived existential
themes [31, 32] utilising selected interview extracts to
illuminate that experience in the parental voice. Figure 1
below summarises the themes and subthemes of the
lived experience of parents of children, adolescents, young
adults with MPS.
Lived relation
The existential theme of lived relation offered insight
into the relational aspects of families’ day-to-day experience
of living with MPS. The families in this study described the
dynamics of relationships in terms of both family relations,
reflecting their immediate family and close friends in a sup-
portive care capacity, and of relations with the healthcare
system and services, as a non-relational relationship. The
two main themes of lived relation were: living with MPS
and living with a rare genetic disease.
Living with MPS
The experience of living with MPS evoked strong emo-
tions in these families, and they described life as charac-
terised by times of uncertainty and ambiguity. They often
described their emotional experience of living with MPS
as being upset, confused, frustrated, and devastated. Some
participants described their life as a roller coaster and liv-
ing with MPS as a constant battle. Parents wanted to be
proactive even though they knew that there was no cure
for their child’s illness. They discussed occasions on which
they had forced themselves to retain a positive outlook to
keep the family together. One parent described her life as
“Exceptionally busy, challenging, the frustrating
challenges in coordinating appointments, coordinating
doctors, and trying to fit everything in” (FA01, pp. 11)
Four subthemes that defined this experience of living
with MPS were identified from parents’ own expressions:
“I have always remained positive”, “we are always proactive
in MPS”, “it is a battle”, and “you are on a roller coaster”.
Unlike other types of MPS, MPS I (Hurler syndrome)
patients have the potential supportive treatment of BMT,
and that can have a positive impact on their day-to-day
lived experience. The extract below outlines how the
parent of a child with MPS I (Hurler syndrome), who
had a BMT procedure, (F7) spoke about being positive
for their child:
“I mean there is not much we can do, we have to get
on with life, and we are not going to give [our son]
back no matter what now, that kind of way, he is such
a great little boy, and we are so happy with him. We
are positive for him, and we hope that we can help
him do so much in his life, that kind of way so that is
all we can do.” (FB07, pp.9) (F7 2ndInterview)
Parents reports of focusing on the good, rather than
bad aspects of being a parent of a child with MPS, and




Lived Relation “Is the lived relation we maintain with others in the interpersonal space that we share with them” (Van Manen, 2007, pp. 104). How we
relate to one another within an interpersonal shared space.
Lived Body Lived body “refers to the phenomenological fact that we are always bodily in the world’” (Van Manen, 2007, pp. 102). The experience
of being a physically or bodily in the world.
Lived Space Van Manen (2007, pp.102) refers to lived space (spatiality) as a “felt space … “.The experience of space in which we find ourselves
affects the way we feel.
Lived Time “Lived time refers to subjective time as opposed to clock time or objective time … and lived time is also our temporal way of being in the
world” (Van Manen, 2007, pp. 104).
Lived Things “The things are our world in its material thing like reality” … How are “things” experienced and how do the experiences of things and
world contribute to the essential meaning of the phenomenon” (Van Manen, 2014, pp. 307).
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that thinking positively demonstrates the use of reframing
strategies by parents whereby they replaced negative emo-
tions with positive affirmations about their child and care-
giving. Parents in this study have also reported that “life is
like a roller coaster”, using this phrase to describe their ex-
perience of fluctuating between the good and bad and to
reflect the progressive nature of their child’s illness.
“…I don't know; it is how you cope and what state of
mind, but emotionally you go through roller coasters,
it is a roller coaster.” (FA01, pp. 14) (F1, 1st Interview)
Families in this study reported that their marital rela-
tionships had become markedly strained. One of the
families separated following their child’s diagnosis.
“He is upset but [son's] dad has always been in denial,
since the day he was born and we found out all this news
he could never accept it, he was just always in denial. He
said that he was fine because he started walking and he
could feed himself and he ended up dressing himself,
putting his trousers on himself, so his dad could never
accept that he was a sick child, that he was terminal. He
just can’t accept it. It upsets him but to him he is just like
a normal child with a few learning disabilities. I don't
think he will ever be able to accept what [son] has and
what he is going through. That is his way of dealing with
it” ((FA06, pp. 11) (F6, 2nd Interview)
In this study, parents used the term roller coaster as a
metaphor to describe the way their emotions changed
over time. This term was used to describe the emotional
impact of illness and the effect of the day to day experi-
ence of living with and caring for their child with MPS.
Living with rare genetic diseases
Parents described their experience of living with a rare
genetic disease in terms of devastation, guilt, and concern
regarding the ability of their child to engage fully with life.
Families in this study reported that they were devastated
by the enormity of the debilitating nature of their child’s
illness and the impact on their child’s life expectancy. They
described this in terms such as “their world crashing down,
feeling guilty, and feeling sorry for him that he is losing
out”. Majority of the parents in this study expressed diffi-
culty in obtaining a diagnosis for their child’s condition,
and they described their journey as long and uncertain.
When they received their child’s diagnosis of MPS, as a
rare genetic life-limiting condition, they reacted with
upset, devastation, anger and shock. It is not unusual for
these parents to experience stress and anxiety about what
the future will bring. All of the parents described the
process of trying to accept their child’s diagnosis in terms
of emotional struggle. One of the parents recalled her ex-
perience of receiving her child’s diagnosis of MPS:
“We were devastated when we heard, we were shocked
because we didn't think it was this condition at all, we
knew nothing about this condition, never heard of it
before.” (FA07, pp. 2) (F7, 1st Interview)
“You could dwell and dwell and think MPS, but you
can't,” (F07), “Upset, confused, frustrated, I didn't
know what was happening,” (F06).
Fig. 1 Summarises the themes and subthemes of the lived experience of parents of children, adolescents, young adults with MPS
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Families in this study disclosed their worry about
watching their child failing to catch up with his/her
peers, and feeling that their child was losing out on a
normal life. They reported that their attention predom-
inantly focused on their sick child resulting in their
healthy child often being left out. One of the parents
expressed concern about their healthy child, describing
how hard it was to manage two lives at the same time:
“Yes it is like having two lives and trying to balance
them in the one house at the same time; it is just very,
very hard. You have got one that needs constant
attention, demands constant attention and you give it
to them because they need it. But you also have
another one who needs attention, but you can't give it
to them because you think I will give it to you later,
you'll be fine”. (FB04, pp. 20) (F4, 2nd Interview)
Families spoke about the devastation of watching their
child failing to grow up as a normal teenager, and the
realisation that the gap would widen as he got older.
They felt that their child was not leading a normal life
and not doing the normal things that other children of
his age were doing:
“I know in years it will be getting harder as he is
getting older, the things that he won't be able to do
that his friends can do and stuff like that. You can see
it now a bit, they want to be going from other places,
and we say, ‘you can't be going.' Even going to a fun
fair, a carnival, he can't go on the rides; he is not tall
enough for this, and that and they are all going on.
Things like that you can see changes in it that are the
condition and how it affects him even friends going off
places and stuff.”(FC03, pp. 8) (F3, 3rd Interview)
The parents in this study described the dynamics of
relationships as both a relational context and non-
relational context. They reflected their experience with
immediate family members, for example, husband, child,
and close friends in a supportive care capacity and their
relation with those in the healthcare system and services
as a non-relational relationship status.
Lived body
The existential theme of lived body reflects how the
body is experienced, perceived, sensed and touched. Ac-
cording to Van Manen [31] (pp. 103), “lived body refers
to the phenomenological fact that we are always bodily
in the world”. The physiological impact of MPS is such
that it has both visible and invisible clinical features.
Two essential themes emerged from the lived body were:
the stigma of a rare disease and MPS as encompassing
multiple diseases.
The stigma of a rare disease
The clinical features of MPS can have a profound effect
on the lived body, and that can lead to stigmatisation of
children with MPS and indeed their parents. As a rare
disease, the effects of MPS conditions can vary from one
type to another. However, nearly all forms of MPS have
physical characteristics that potentially cause visible
stigma. Common features across types of MPS include a
big head with depressed nasal bridge, thick bulging lips,
enlarged tongue and coarse straggly hair – visible signs
which contribute to the characteristic look of these
patients. Children with MPS may also have concealed
symptoms eg: learning disabilities and this can cause
invisible stigma.
Parents in this study spoke about their fear of the visibil-
ity of MPS and how clinical features that were not obvious
at birth gradually became prominent as they became
older:
“Yes diagnosed at 3½, yes it is weird enough because
you go back thinking how come it wasn't picked up at
the start? I suppose you never check for these things
because he looks normal, he is born normal, normal
weight. His features probably hadn’t come out by then
…”. (FA03, pp. 13) (F3, 1st Interview)
Another parent spoke about their realisation that some
warning signs were visible from the beginning, but went
unrecognised since their child was reaching all the de-
velopmental milestones:
“Because we know what we know now we can see
certain signs were there from [their child’s] birth like
the hairy back, the protruding stomach … but they
were just little things. Development wise he was hitting
all the milestones, everything like that, so we didn't
think anything was wrong. And then when we did
get the diagnosis, yes, it is hard to accept there is
something wrong with your child.” (FB02, pp. 3)
(F2, 2nd Interview)
Parents in this study felt that their child was not
treated as ordinary by the general public, and the pub-
lic’s reaction to them was considered as stereotypical
and negative. Parents spoke about how individuals looked
at their children’s peculiarities, and how they sensed that
there was something wrong with their children.
As one of the parents stated:
“People stare at children a lot, and they look at him
funny. Kids can be ok; it is adults that are worse.
‘What is wrong with him, and what will happen to
him, will he grow?' They are very nosey; they just want
to know things but things like that annoy me, the way
Somanadhan and Larkin Orphanet Journal of Rare Diseases  (2016) 11:138 Page 6 of 14
they talk. But [child] is great; he gets on with it…
Things like that are a bit tough with him.”
(FA03, pp. 3) (F3, 1st Interview)
The need for parents to protect their children was
clearly evident in this study. Parents felt that it was their
responsibly to protect their children from the prying
eyes of society. Parents narrated their experience of not
treating their child any differently from others in society.
MPS as encompassing multiple diseases
Families described the experience of understanding dif-
ferent types of MPS such as MPS I-IV and VI, and they
spoke about their awareness of the considerable variety
of physical and mental characteristics presented by pa-
tients. They were able to identify which types of MPS
were associated with normal intellectual functioning and
which were not. The family of a child with MPS III
compared their child with children who had other types
of MPS:
“And then people with MPS6, 4 and 1, they can join
the conversation from early years up until the later
years, adulthood, and join in the conversation and
even some of them have a drink and all. Whereas we
go from dealing with a very hyperactive child to
progressing into a child who can't speak, no
understanding and is 24–7 dependent. So you lose out
in a big way. It is all MPS but totally different
diseases.” (FA04, pp. 13) (F4, 1st Interview)
Likewise, a family of children with attenuated MPS I
spoke about their feeling for children with other more
severe types of MPS:
“And you see other parents, I mean the MPS disorder
is horrendous, certain ones, Hurler's, Sanfilippo,
Hunter's, I mean we have lost so many children. And
they have a short life expectancy. We feel luck that we
got the ...., which sounds terrible because life expectancy
is normal once you are managed and maintained. …
that it is not cancer, that is it not Sanfilippo, that it is
not Hunter's, so that is probably a way of coping. We
have probably taught ourselves to cope that way.”
(FA01, pp. 16–17) (F 1, 1st Interview)
There were two families in this study whose children
had progressed to a stage where no further treatment
options were available. This was particularly notable in
the case of the young adult with MPS III (Sanfilipo):
“I was fuming because kids with cancer, there is
treatments available for some of these kids, whereas
there is no treatment for our child. What is the
difference? In fact, it is worse. I would rather [my
child] be diagnosed with maybe a small tumour when
my child was four. Our child could be in college now.
Whereas MPS has just destroyed my child’s body …”
(F B04, pp. 8) (F4, 2nd Interview)
The existential theme of lived body reflects on the im-
pact the disease has on the physical body. This theme
was illustrated in parents’ reflections on the progressive
nature of MPS in children and its impact on the family’s
life. Language used to express this theme included de-
scriptions of devastation, guilt, concern about the impact
on their child’s ability to engage fully with life, and their
fear of how the increasing evidence of visible clinical
features of MPS reflected their child’s bodily experience
of this condition.
Lived space
Space was another important theme, which emerged in
relation to the transitional process the families were ex-
periencing. They spoke interchangeably about time and
space, with spatiality considered as a ‘no man’s land,'
where they felt they were oscillating between the past,
present and future due to the uncertainty in their child’s
life. Two main themes emerging in relation to space
were: Unknown future, and hospital vs. home.
Unknown future
Families described their experience of living in a space
in which the future is unknown from the time that they
were told of the prognosis and outcome for their chil-
dren. Parents in this study spoke interchangeably about
time and space. They felt that living with an unknown
was a horrendous experience because of the limited
treatment option. They described this experience of
space as being in no man’s land or being trapped. These
families described their lived space as uncertain, ambigu-
ous and stressful, knowing that their child is living with
a condition with a limited treatment option.
Families described their experince of powerless and
endless worry about their child’s prognosis and the pro-
gressive nature of the condition. One parent described
the experience of being trapped eloquently:
“It is a constant worry. You are constantly worrying
about what they are going to say because you are
afraid that you have missed something that they have
seen, and you just feel like your life is trapped. You feel
like you are in a box, and you just can't get out of it”.
(FC06, pp. 9)(F6, 3rd Interview)
Families described their experience of living in an un-
known future from the point of which they were told of
the prognosis and outcome for their children but also as
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a cyclical process, with the same fears and worries com-
ing to the fore each time they engage with services.
“The future is unknown because every time we go to
see a doctor, like today I am going to see a neurological
doctor with my son, you worry every time you go to see a
doctor because you don't know what they are going to
find or not find.” (FA01, pp. 3) (F1, 1st Interview)
“No man’s land” is a term used by many families in
this inquiry as a way of describing their experience of
living with this condition. This space is described as a
lonely and unending journey. Such feelings of uncertan-
ity are prominent in this group of families who face the
transition stage where they no longer belong to the pre-
vious status, yet have not completed the passage to the
next [36, 37]. Parents described their life as oscillating
between the past, present and future space of uncer-
tainty in relation to their child’s life.
“Fine if your blood pressure is high or low because you
can cope with something that is within somebody's
grasp, but that was way beyond both our grasps. It
was a horrendous time, I have to say, horrendous
because when we found out about it, there was no
cure, there was no treatment, so we were in no man's
land. They are now on treatment but back then there
was no treatment. Looking back now there was trials
that we were unaware of that were happening, but it
meant nothing to us”. (FA01, pp. 6) (F1, 1st Interview)
From the families’ perspective, they are living in a
space of ambiguity, where they don’t know what is ahead
and described feelings of being trapped in a box or
square that they couldn’t get out of.
Hospital Vs. Home
The concept of space in hospital versus space at home
was a notable factor in the lived experience of parents in
this study. Unlike a parent of a child with a temporary
illness, such as the flu, parents of children with MPS
have to adapt to the fact that their illness is chronic and
may deteriorate. These children and their families spend
significant periods of time in hospital. All the children
except one were initially treated with weekly Enzyme
Replacement Therapy (ERT) in the national metabolic
service. At the time of the study, five children were re-
ceiving weekly ERT at home. Three of the children with
MPS I (Hurler syndrome) in the study had received
Bone Marrow Transplant (BMT) outside Ireland fol-
lowing an initial period of ERT treatment. Parents of
children receiving home treatment expressed satisfaction
with moving from weekly hospital ERT to home-based
treatment. The subthemes that emerged from the parent's
own expressions are: hospitals bring you back to reality,
you are in your home and do your own thing, and the
healthcare system as a revolving door.
Families reported positive effects of home ERT when
they compared their weekly hospital commitment to
treatment for their children. They preferred to be in
their home rather than a hospital, and they felt being in
their particular home aided the development of routine
and structure in their regular life. This parent expressed
her experience of being at home for her son’s ERT:
“You are in your home and do your own thing and get
on with it if you need to. You are not waiting in the
hospital all day long; you can be there getting the
dinner or doing the household chores and stuff. And
he is more relaxed at home because his friends can
call and that, now they are on the summer holidays
they can play away and stuff.”(FC03, pp. 4) (F3, 3rd
Interview)
The family of a child with MPS I who went for BMT
outside Ireland expressed how they felt great to be com-
ing back home after six months of treatment. They also
spoke about the frustration of leaving family behind for
six months to go outside Ireland to get treatment for
their sick child.
“But it was just great to be home. After being away
nearly for six months it was different coming back
then, but it is just great to come home.” (FB07, pp. 5)
(F7, 2nd Interview)
Families described hospital as a wide-open space that
made them feel exposed to the reality of having a child
with MPS. They felt that healthcare professionals’ know-
ledge on MPS might be limited considering the rare nature
of the disease. They recommended having a dedicated
space such as a centre of excellence of rare diseases, to
facilitate education, training, and research and expand
knowledge and practice in this area:
“I think we do need our centres of excellence to be
tapped into the centres of excellences of every other
country so that we are teaching each other because
this is all teaching … These are all the things we have
to share because our society of these conditions is too
small within certain countries. So definitely I think,
and the world is built that you can do that, you can
share the information with hospitals.” (FB 01, pp. 16)
(F1, 2nd Interview)
“There has to be a centre of excellence, 100 % and I do
believe, I mean with MPS and other conditions …”
(FB01, pp. 15) (F1, 2nd Interview)
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Families spoke about their experience of the home as a
space of comfort or contentment. When they spoke
about their home they described feelings of security and
protection. In this study, families disclosed their experi-
nce of having spent time outside the country away from
home and they described feeling a sense of belonging
and comfort when they returned to their home and were
united with their family members. There was also a sense
that MPS and its progressive nature changed families’
sense of space, as their priorities change. One of the fam-
ilies shared their experince of adapting their house and
room to suit their child’s ongoing behavioural challenges
and safety issues.
Families reported that they felt vulnerable due to that
fact that collaboration and communication between health-
care service providers are often fragmented and unsatisfac-
tory. They expressed disbelief and frustration towards
healthcare systems and felt that these systems had little un-
derstanding of what challenges parents of children with
MPS experience in their day-to-day life. They described the
current healthcare system as being like a revolving door.
“So you go through, it is like a revolving door, you go
in, you go out, you go in, you go out, and you are only
the number of the day, and the doctor and the patient
can make it special. But to the system, I don't think it
is a caring enough system.” (FB01, pp. 17) (F1, 2nd
Interview)
One of the parents described feelings of anger, frustra-
tion, and disbelief towards the health service, and she
believed that system had no understanding of families
day to day experience. There were numerous occasions
she “just felt like walking, just going away and never
coming back”, and she described the process by which
decision were made by the healthcare system as taking
too long.
“So it is frustrating that this process is taking so long. I
would love like if there was a miracle like I know he
can't be put on this treatment willy-nilly, there is a
process, but the process, from a parent's perspective, is
so long, it is taking far too long to be sorted. There
were times I just felt like walking, just going away and
never coming back; it has just been so hard.” (FC02,
pp. 5) (F2, 3rd Interview)
Families reported numerous challenges and frustra-
tions with the current health system. They reported that
corordination and communication between healthcare
services are fragmented. For example, families reported,
“trouble from one hospital getting an x-ray to another hos-
pital.” They also communicated concern over shortcomings
in the current healthcare services, which intensified their
apprehensions regarding their child’s future. Families in this
study spoke interchangeably about time and space. The ex-
istential theme of lived space rather than mathematically
measured space expressed how these families experienced
different spaces in their day-to-day lives.
Lived time
The existential theme of lived time describes how time
is experienced in the parents’ day-to -day life caring for
their child, adolescent and young adult with MPS. There
was a reciprocity in how parents talked about time and
space. They described being frightened as a result of the
lack of cure or treatment for their child’s illness, and the
feeling that the future is obscure to them and their chil-
dren. They described periods of waiting as distinct from
periods in which they are actively involved in engage-
ments. The following themes emerged from lived time:
the experience of waiting and a tough road ahead. Families
spoke about their day-to-day lived time, their hope, expec-
tations, and the uncertainty of their life to come.
Experience of waiting
Parents in this study reported the frustration of waiting
for a long time for a diagnosis, to get a medical card for
their child and to get basic needs like a wheelchair for a
child with a physical disability. Early diagnosis and inter-
vention in rare diseases can improve an individual’s life
expectancy and QoL. It can also provide important in-
formation to guide further reproductive choices for the
family. The subthemes emerging from parents expan-
sions were noted as; you are left waiting, waiting and
waiting, and it’s like watching a time bomb.
“Yes, it is tough although we expected it, we have been
told it would happen, but you are never ready to hear
it …And it is just so frustrating, and it is sad to see
everything being taken away from him, the work we
put into doing what he does now and what he did
before. And it has just been taken away from him bit
by bit because the condition is eating away at him.”
(FC06, pp. 4) (F6, 3rd Interview)
Families experienced difficulties in accessing additional
medical and non-medical services for their children.
They spoke about spending significant amount of time
navigating bureaucracy instead of caring for their sick
children. One of the families discussed the issue of wait-
ing to get a wheelchair for their child at the first inter-
view in December 2013, and they were still waiting for
the wheelchair at their 3rd interview, a year later:
“Yes, we are still waiting on our wheelchair. There was
supposed to have been an assessment done in August,
and he [husband] got sick again when he came back
Somanadhan and Larkin Orphanet Journal of Rare Diseases  (2016) 11:138 Page 9 of 14
home he got sick again, and I had to ring them and
cancel them, and they said they would send me out an
appointment. It is only now I realise they haven't sent
an appointment.” (FC04, pp. 32) (F4, 3rd Interview)
Families described the emotion of watching their child’s
progression as like watching a time bomb. A parent
recounted her experience:
“…Any parent who is given a diagnosis of their child
having a life threatening condition, a terminal
condition, of course, your world is going to come crashing
down because you don't know what is ahead of you. And
that is the thing; we know this condition is progressive,
we don't know when [son] will start to deteriorate. It is
just like watching a time bomb. Like every little thing,
you are wondering is this the start of it or whatever…”
(FB 02, pp. 4) (F2, 2nd Interview)
They spoke about their collective experience of wait-
ing: waiting for their child’s diagnosis, waiting to access
expensive ERT treatment, and persistent waiting to get
additional support mechanisms from the government
agencies.
A tough road ahead
In this study, families expressed subjective time opposed
to clock time. They spoke about their day-to-day lived
time, their hopes and expectations. Their experience
showed that lived time and lived space are mingled; they
spoke about the uncertainty in their life and not knowing
what to expect.
Families expressed their powerful emotions at the differ-
ent stages of their child’s illness when they found out
MPS is a progressive life-limiting condition with no
curative treatment options available at that time. Families
expressed their emotion of watching their child’s progres-
sion as like watching a time bomb. A parent recounted
her experience:
“…Any parent who is given a diagnosis of their child
having a life threatening condition, a terminal condition,
of course, your world is going to come crashing down
because you don't know what is ahead of you. And that is
the thing, we know this condition is progressive, we don't
know when [son] will start to deteriorate. It is just like
watching a time bomb. Like every little thing, you are
wondering is this the start of it or whatever. And then the
only thing that gives you hope is when he comes to his
check-ups and you get great news you know he is ok.”
(FB 02, pp. 4) (F2, 2nd Interview)
Family of the young adultd with MPS III spoke of
how their child had continued to deteriorate over the
years, and this was clearly evident from their multiple
interviews.
“It changes over the years. The child we have now,
even though our child is 20 is a completely different
child that we had when our child was 3, when our
child was 9. It changes completely and it is very hard
to realise that you have to change with our child…
Yes, the condition is probably less mentally draining
now and more physically challenging”. (PA04, P-3)
(FA04, pp. 3) (F4, 1st Interview)
“…So we probably feel a little more vulnerable now,
and a little more shook up because the condition has
very gradually changed from day one.” (FB04, pp. 3)
(F4, 2nd Interview)
Regardless of their worry about their children's future
and their knowledge of the tough road ahead of them,
the families were also living in a present time. They con-
sidered themselves frequent flyers who lived life day by
day. The existential theme of time described how time is
experienced in the parents’ day-to -day life caring for
their child, adolescent and young adults with MPS. Van
Manen argued [32], (PP.306), “we experience the time of
waiting differently from when we are actively involved in
something”, and he also highlighted that lived space and
lived time are often interlinked. Parents talked about
time and space in a reciprocal way and described finding
their lived space frightening as a result of the lack of cure
or treatment for their child’s illness and the fact that the
future is obscure to them and their children [38].
Lived things
The existential theme of materiality reflects how things
and technologies are influenced in thier day to day life
while caring for their child. Van Manen [32] argued that
it would be difficult to overestimate the significance of
things in our day-to-day life. Lived thing comprised a
theme that was reflective of the impact material things
had on the phenomenon of parents’ experience of living
with and caring for MPS – i.e. things in their day-to-day
life with MPS.
Things in their day-to-day life with MPS
Families described how material objects, for example,
phone, the internet, hoist and wheelchair were devices
that reinforced the reality of their living with a child
who had complex needs, and how such objects could
impact negatively or positively on their life.
One of the families indicated that they found a hoist
as a great help when it came to caring for their young
adult, who was physically challenging for the parents.
They spoke about things in their day-to-day lives, such
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as nappies, wipes, and wheelchairs. They also pointed
out that how important it was for them to have a wood-
burning stove, because their child was very prone to
hypothermia:
“The hoists are great, but it still involves a bit of lifting
and what have you. But that is where we are at the
moment, she is just physically challenging more so,
and it requires teamwork. Even going on a trip in the
car, it is like packing to go on a holiday sometimes with
nappies, wipes, feed, emergency stuff and then getting
her into the wheelchair van, up the ramp, securing her.
It is just … When you are going out for a day you make
the most of it.” (FA04, pp. 4) (F4 1st Interview)
It has been reported that searching for easily under-
standable rare disease-related information by individuals
and their family members can be difficult, and when
information is found it can be a frustrating and scary
experience [25]. Families reported on the strengths as
well as the risks of internet usage in searching for in-
formation on rare disorders. On numerous occasions,
they felt the internet could be a wonderful tool, and
they also spoke about the internet as a dangerous tool.
When a child is diagnosed with a rare genetic life-
limiting illness, parents are regularly pushed into a whirl-
wind of feelings. Experiences around the time of the diag-
nosis were discussed earlier, but here we focus on the
manner in which the diagnosis was disclosed or managed
by the healthcare professionals over the telephone. This
mode of communication can have a critical and substan-
tive effect on parents’ psychological wellbeing. The major-
ity of the families spoke about their dissatisfaction with
the manner in which the diagnosis of MPS was disclosed
over the phone. They felt it was horrendous, and predom-
inately spoke about how the “thing” (i.e. the “phone”) af-
fected them in their day-to-day life. One parent described
this experience as follows:
“Over the phone it was horrendous for the reason
being I had no support around me, I was at home, the
children were at school or crèche or wherever they
were and the name Mucopolysaccharidoses was way
beyond my comprehension of a word I had ever heard
of before. It sounded big, and it sounded serious and it
was just an awful way to be told. Automatically I said,
’ have to get my husband to ring you.' Because I
couldn't take it in, even though I didn't know what it
meant, I knew it didn't mean something good.” (FA01,
pp. 6) (F1, 1st Interview)
Likewise, another family expressed recollection of
and their experience of hearing their child’s diagnosis
of MPS:
“He said he would let us know, but then he rang. It
was bit weird when you think of it. Then we had to go
for a meeting with him anyway but he had actually
told us over the phone. It is probably not the right way
to tell you something, is it? It would be better off going
into his office and putting it all in front of you. But he
would tell you again, as I said we went off then of
course but by the time we got to see him we had all
these things got, people had got stuff off the internet for
us, booklets, downloading whatever all and printing off
sheets. Maybe you are better off coming in and discuss
what is wrong or whatever; we would have been better
off that way. Because you are looking it up and it is
not great.” (FB03, pp. 4) (F3, 2nd Interview)
Families spoke about how the internet has become a
helpful tool and their experience of searching on the
internet and looking for information on their child’s ill-
ness following diagnosis. Some of the parents in this
inquiry use Facebook as a mode of communication and
update, and they found it very beneficial for networking
and supporting other families with a similar rare condi-
tion like MPS.
Discussion
The purpose of pursuing this inquiry was to gain a dee-
per understanding of what it is like to be a parent of a
child, adolescent or young adult with MPS. The main
themes emerged from this study were described as living
with MPS, living with a genetic rare disease, the stigma
of a rare condition, MPS as encompassing multiple dis-
eases, Unknown future, hospital vs. home, experience of
waiting, a tough road ahead, and things in their day-to-
day life with MPS. The majority of families started their
lived experience from the time they received their child’s
diagnosis and this diagnosis then impacted their life as a
whole. They spoke about emotional reactions and coping
strategies associated with both diagnosis and the on-
going challenges of living with a progressive condition
that has no cure. They spoke of their child’s QoL, their
healthy children’s wellbeing, and for some, the impact
on their own physical and psychological wellbeing. They
also reflected on issues of stigmatization and isolation in
their experience of living with a child with a rare disorder.
Even though the impact of child’s rare life-limiting illness
on parents has been explored in a number of studies
[13, 14, 18, 39–41] this study is the first of its nature
that has explored the experience of Irish parents living
with and caring for a child, adolescent and young adult
across the full spectrum of MPS diagnoses.
This study’s findings reflect the wider literature look-
ing at the impact of other types of life-limiting illness,
which have also indicated that caring for someone with
MPS has a wide impact across all dimensions of the
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family’s life [13, 14, 39–41]. These findings are again
consistent with the literature on parents of children with
other life-limiting conditions [13, 14, 39–41] and life-
threatening conditions [42, 43]. Equally consistent with
the literature was the picture that emerged of parents
adapting and fitting in around their child’s increasing
needs, as their illness progressed [13, 14, 44]. Families
described their evolving role of a parent to a main care
provider, with mothers acting as the principal care pro-
viders among those interviewed. Only one father was
interviewed, although the invitation to participate was
open to both parents, either together or separately. Fa-
thers clearly play an important role in these children's
lives, and take on roles of protecting and providing care
for their family. However, the study findings are
consistent with literature which shows that women
continue to primarily take on the role of caregiver
when a child has a life-limiting illness [45, 46]. The
notable concern on the part of parents for their
healthy children's welfare is expressed in this study
and is mirrored in other literature [47–49]. Studies
have consistently shown that having a rare disorder
gives rise to family problems, strain on marital rela-
tionships, feelings of isolation and additional financial
pressures, as well as having a negative impact on
healthy siblings [12–14, 20, 50].
This study also highlights the inadequacy of communi-
cation skills among healthcare professionals, especially
during the initial diagnostic disclosure. The study findings
are consistent with other published studies on challenges
in the way in which terminal illness diagnoses are dis-
closed to families [20, 51, 52]. The majority of the families
in this study did not receive their child’s diagnosis of a rare
life-limiting condition face to face in the clinic and were
dissatisfied with how healthcare professionals disclosed
their child’s diagnosis, particularly in instances where diag-
nosis was given over the phone. Of note, the majority of
the families were not referred to, or attending, the national
centre that provides specialist care for MPS at the time of
diagnostic disclosure. There is the need for clear national
clinical pathway or guideline to manage the assessment of
diagnosis and breaking off bad news. This study also re-
ported that the healthcare professionals’ lack of specialist
knowledge of the rare condition raised challenges with
diagnosis and appropriate specialist referral. There is a
need to develop a competency framework for rare diseases
to avoid any unnecessary delay in referral, diagnosis, and
disease management or treatment.
This study highlighted the need for greater and more
diverse initiatives that could serve as indicators for the
future understanding and development of policy and
practice related to paediatric rare life-limiting conditions.
Even though parents reported some positive aspects of
current services, e.g. their relationships with primary
healthcare professionals and the quality of services they
currently receive, the overall findings of the study high-
light difficulties in accessing services. Parents described
inconsistent and inequitable services often characterized
by bureaucracy and delay. Despite findings from across
studies [21, 39, 44, 51] there is a consistent shortfall in so-
cial, emotional and respite support for families of children
with MPS. The study findings highlighting the need for
more responsive physiotherapy, occupational therapy,
psychology and social support services at the regional cen-
tres. The study findings reflect other studies which suggest
that family needs are subject to change over a period [13,
14, 21, 53, 39, 44, 51]. Study findings highlight the import-
ance of frequent and planned re-assessment of the social,
emotional, and economic challenges experienced by chil-
dren and their families [54]. The findings also point to un-
met mental healthcare needs among parents. If these
unmet needs are not addressed, there is a risk that
these families will experience negative consequences
additional to the already high burden and cost of
their child’s condition. There is also need to set out a
process framework on six monthly to annual review to
assess and advise families needs and psychosocial support
services in the care of children with rare progressive disea-
ses.The findings of the study recommend having a desig-
nated key worker role in the care and management of
children with MPS and related diseases. This position will
help to enhance parents trust in the health system and
overall coordination to minimise waste of time and
resources.
Families reported that their experience of partcipating
in the research interview was equal to a counselling session
or as a therapeutic relief from their stress, but expressed a
sense of limbo when the research interviews were com-
pleted. However, the purpose of the research interview was
not intentionally offering any form of therapy, despite the
participant report. This study suggests that researchers
should be aware of the qualitative therapeutic interview
process and its possible benefits for the participants’ emo-
tional wellbeing throughout the research process, that is
also mirrored in other literature [55, 56].
Study limitations
There are some advantages as well as disadvantages to
using phenomenology as a research methodology. The
subjectivity of the data could lead to difficulties in es-
tablishing what may be considered a more generalised
approach to reliability and validity. Further, the small
sample size and uniqueness of lived experience can be
challenging in making an inference for a wider cohort
or group. There were consequent organisational changes
following recommendation made in the national plan for
rare diseases [23], and the recent establishment of an adult
metabolic centre may have created some uncertainties
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among these families. Finally, as already acknowledged,
this study provided an interpretation of the lived experi-
ence of parents of children, adolescents or young adults
with MPS at particular moments in time, and not at the
point of diagnosis. It also did not follow parents through
the end stage of their child’s condition. A study that
adopted a strategy of longitudinal engagement over a
longer period, including both diagnosis and death, while
posing challenges in terms of feasibility would be optimal
for a complete understanding of the phenomenon.
Future research
The study suggested that there are many aspects of the
care of children, adolescents or young adults with MPS
that require further research attention. This study in-
cluded serial interviews spanning a time period of one to
two years, and as such attempted to capture the progres-
sive nature of this illness and its impact on children and
their families. However, the findings point to the need
for future research into the experience of living with
MPS from the children’s or individuals’ perspective, spe-
cifically to investigate various aspects of this chronic de-
bilitating illness. These aspects might include how the
patients perceive themselves (self-image), how the child
or adult with MPS copes with issues such as stigma and
engagement with services, and what they feel about ERT
or BMT. To date, the healthcare professionals caring for
the children with MPS have not been afforded the op-
portunity to describe their experience of caring. To ad-
dress the lack of formal research into the healthcare
professionals’ experience of caring for the children with
MPS, this study recommends further research into health
professionals’ perspective to complement the findings of
the current study. Further research is also recommended
to explore the level of support each separate family mem-
ber requires, including healthy siblings and grandparents,
as well as investigating the needs of families in relation to
the long-term care of their child through adolescence to
adulthood and the specific services required at different
points of the disease cycle.
Conclusion
This research study is the first of its kind to act as an
initial enquiry and to generate knowledge through
researching the lived experience of Irish parents’ of chil-
dren, adolescents and young adults with MPS. This
study provided a voice to the Irish parents of children
with MPS, and in doing so will make their lives more
understandable to the wider audience. It brings to light
the uncertainty, sorrows, and everyday challenges faced
by these families, and hopefully will improve the care
and support for them through the many months and
years of their child’s illness.
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